PI Industries Q1 FY27 Results & Earnings Intelligence
PIINDStructural risk assessment following Q1-FY27 | 30 Jun 26 earnings.
₹1,766.4 Cr
-11.1% YoY•+7.7% QoQ
₹319.9 Cr
-36.6% YoY•+6.6% QoQ
₹244.2 Cr
-39.0% YoY•+22.0% QoQ
43/ 100
−9 pts QoQ
The Quarter at a Glance
Consolidated Financials| Metric | Q1-FY27 | 30 Jun 26 | Q1-FY26 | 30 Jun 25 | YoY Δ | Q4-FY26 | 31 Mar 26 | QoQ Δ |
|---|---|---|---|---|---|
| Total Revenue / Income | ₹1,766.4 Cr | ₹1,986.4 Cr | -11.1% | ₹1,640.8 Cr | +7.7% |
| Profit Before Tax (PBT) | ₹319.9 Cr | ₹504.6 Cr | -36.6% | ₹300.1 Cr | +6.6% |
| Net Profit (PAT) | ₹244.2 Cr | ₹400.0 Cr | -39.0% | ₹200.2 Cr | +22.0% |
Sources:Official BSE/NSE Disclosures & Financial Filings
Sentinel Executive Summary
Core Earnings Synthesis"PI Industries Limited currently sits within Flagium's Moderate Deterioration category. However, recent periods have introduced early signs of competitive and operating pressure, leverage and funding pressure. With both revenue and profit contracting, triggers like 'Governance Integrity Shock', 'Margin Compression' amplify the structural risk. The combination of active triggers indicates escalating structural vulnerabilities that require active monitoring."
PI Industries Limited registered a drop in both quarterly revenue and net profit, reflecting challenging industry-wide demand trends. A 'Moderate Deterioration' risk classification and 4 active flags indicate that operating headwinds are beginning to translate into structural pressure.
🟢 Key Operational & Structural Positives
- ✓Operating Margins: Operating margin moved -729 bps YoY and -30 bps QoQ to 18.11%.
⚠️ Key Areas of Watch & Margin Pressures
- ⚠Resolution of 'Operating Leverage Stress' warning: Expenses are consistently growing faster than revenues, creating operational pressure.
- ⚠Raw material price movement and its impact on operating margins.
- ⚠Working capital efficiency and cash flow conversions.
Total Revenue / Income contracted -11.1% YoY due to a challenging prior-year base, but rebounded +7.7% QoQ vs Q4-FY26. Sequential inflection signals improving run-rate momentum. Bottom-line rebounded in lockstep (+22.0% QoQ), signaling operational stabilization.
Flagium Risk Signals
Automated Forensic SignalsStabilization in key metrics • Persistent watch: Governance Integrity Shock • Persistent watch: Margin Compression • Persistent watch: Relative Growth Weakness
PIIND: Key governance event detected: DIRECTOR_RESIGNATION.
Operating margin declined by 7.3 bps YoY for two consecutive quarters.
Revenue growth consistently lags behind sector median (18.7%).
Expenses are consistently growing faster than revenues, creating operational pressure.
Capital Allocation & Shareholder Return
DividendBoard approved capital distribution for Q1-FY27
₹10.00 / share
Approved by Board07-Aug-2026
Shareholder Cut-offReported
Earnings BackedWithin 30 Days
Statutory Window🎙️ PI Industries (PIIND) Q1 FY27 Concall Intelligence
Management Commentary, Concall Takeaways & Key Discussion Themes
Source
Investor Call / Analyst Meeting
Transcript
View Full Transcript ↗Management Tone
Bullish
The call focused on PI Industries’ innovation-led growth, expansion into adjacencies, and resilience despite industry headwinds, with management forthcoming about both opportunities and challenges.
Key Themes & Management Discussion — PIIND Concall Takeaways
Guidance & Outlook
Management reiterated confidence in a positive growth trajectory for FY27, expecting recovery in exports and scale-up in pharma and biologicals, while maintaining discipline in capital allocation and margins.
“We expect FY27 to be better over FY26 driven by recovery in exports in second half supported by new product launches and gradual scale up of pharma and global biologicals.”
Innovation & R&D
PI emphasized its investments in R&D, new molecule launches, and differentiated capabilities as the foundation for long-term value creation and competitive advantage.
“Our first NCE, Pioxaniliprole, an insecticide, discovered in India, for Indian farmers and now to go to global farmers is set to launch in the domestic market very soon awaiting regulatory approvals.”
Biologicals Expansion
The company highlighted aggressive growth in biologicals, successful field trials, and positive feedback in global markets, positioning biologicals as a key growth driver.
“Biologicals have shown an aggressive growth of 50% with a three-year CAGR of 15%.”
Exports & Operating Environment
Management acknowledged continued challenges in the export business due to soft commodity prices, muted crop economics, and geopolitical uncertainties, but expressed confidence in the business model and future recovery.
“With respect to our exports business, the operating environment continues to remain challenging.”
Pharma & Adjacency Expansion
PI is seeing early positive signs in its pharma CRDMO strategy, with investments in capabilities and regulatory approvals, and expects this to be a long-term value driver.
“I am also happy to inform that slowly but steadily we are moving in the right direction in our pharma play and seeing early positive signs of transforming into a differentiated CRDMO organization.”
Risks Mentioned by Management on Call
Risks Acknowledged in PIIND Concall
- •Erratic weather and climatic situations impacting domestic agri demand“The industry remains cautious and watchful of erratic weather and climatic situations which will impact consumption patterns.”
- •Pricing pressure and high input costs“There are pressure on margins due to high input cost & higher levels of inventory, however we believe consumption patterns will see a positive trajectory.”
- •Geopolitical uncertainties and tariffs affecting exports“This is further compounded by rising costs due to geopolitical uncertainties, genericization pressures and tariffs.”
- •Volatility in raw material prices“While margins remain robust, we continue to closely monitor the operating environment, given the volatility in the raw material prices.”
- •Delays in CRDMO/pharma order execution“And clearly sometimes there are sequential delays but eventually they come if you are locked in with a customer.”
Sentinel Cross-Check: PIIND Management Claims vs Financial Signals
Comparing what PIIND management said on the call vs what Flagium's financial signals detected.
Governance Integrity Shock
Management Commentary
Delays in CRDMO/pharma order execution
Financial Signals
PIIND: Key governance event detected: DIRECTOR_RESIGNATION.
Sentinel View
Management acknowledged this pressure on the call, so the signal and the commentary agree.
Margin Compression
Management Commentary
Volatility in raw material prices
Financial Signals
Operating margin declined by 7.3 bps YoY for two consecutive quarters.
Sentinel View
Management acknowledged this pressure on the call, so the signal and the commentary agree.
Relative Growth Weakness
Management Commentary
Management reiterated confidence in a positive growth trajectory for FY27, expecting recovery in exports and scale-up in pharma and biologicals, while maintaining discipline in capital allocation and margins.
Financial Signals
Revenue growth consistently lags behind sector median (18.7%).
Sentinel View
Management's outlook is constructive, but the improvement is not yet visible in the reported numbers.
What to do next
Explore PIIND's full structural risk profile — 12Q score trajectory, pillar breakdown, flag history, and peer benchmarking.
View PIIND profile →See how Chemicals peers and the broader market are positioned. Identify sector-wide stress or rotation signals.
Open market monitor →Check how this Q1-FY27 | 30 Jun 26 result affects your portfolio's overall risk exposure and concentration.
Review your portfolio →Continue Research
📬 Flagium Risk Brief — Track forensic risks on PIIND & 3 market anomalies weekly
See a sample issue →Methodology & Regulatory Disclaimer
Flagium AI is an automated financial data analytics platform. Analysis reports are compiled programmatically from public regulatory XBRL submissions (NSE/BSE) for educational and research purposes only. Flagium AI is not registered with SEBI as a Research Analyst or Investment Adviser under SEBI regulations. This evaluation does not constitute investment advice, financial planning, or recommendations to buy, sell, or hold any security.
Investments in securities market are subject to market risks. Read all the related documents carefully before investing. Please consult a SEBI-registered Investment Adviser before acting on any data presented.